Acitretin | hsa00480 | Glutathione metabolism | 3.29E-04 | 4 | Q9UJ14, Q16772, P09211, P30041 | GGTL3, GSTA3, GSTP1, PRDX6 | More | |
Acitretin | hsa00520 | Amino sugar and nucleotide sugar metabolism | 7.87E-03 | 3 | Q16222, Q9Y223, P06865 | UAP1, GNE, HEXA | More | |
Acitretin | hsa00533 | Glycosaminoglycan biosynthesis - keratan sulfate | 3.43E-02 | 1 | Q9NY97 | B3GNT2 | More | |
Acitretin | hsa00562 | Inositol phosphate metabolism | 1.28E-02 | 2 | Q14642, P29218 | INPP5A, IMPA1 | More | |
Acitretin | hsa00603 | Glycosphingolipid biosynthesis - globo and isoglobo series | 4.30E-03 | 2 | P06865, O75752 | HEXA, B3GALNT1 | More | |
Acitretin | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 5.46E-03 | 2 | Q16772, P09211 | GSTA3, GSTP1 | More | |
Acitretin | hsa00982 | Drug metabolism - cytochrome P450 | 1.06E-02 | 2 | Q16772, P09211 | GSTA3, GSTP1 | More | |
Acitretin | hsa00983 | Drug metabolism - other enzymes | 1.72E-02 | 2 | Q16772, P09211 | GSTA3, GSTP1 | More | |
Acitretin | hsa01100 | Metabolic pathways | 9.02E-04 | 16 | P35790, Q16772, P09211, Q9UJ14, P30041, Q14642, P29218, P40926, Q7KZN9, Q14376, P15121, P07101, Q9UHK6, Q86VZ5, Q9BQB6, P12074 | CHKA, GSTA3, GSTP1, GGTL3, PRDX6, INPP5A, IMPA1, MDH2, COX15, GALE, AKR1B1, TH, AMACR, SGMS1, VKORC1, COX6A1 | More | |
Acitretin | hsa01522 | Endocrine resistance | 4.74E-02 | 3 | P22694, P10415, Q13323 | PRKACB, BCL2, BIK | More | |
Acitretin | hsa01524 | Platinum drug resistance | 3.80E-03 | 4 | O15392, Q16772, P09211, P11388 | BIRC5, GSTA3, GSTP1, TOP2A | More | |
Acitretin | hsa03018 | RNA degradation | 5.00E-02 | 1 | Q9NQT4 | EXOSC5 | More | |
Acitretin | hsa03020 | RNA polymerase | 1.81E-02 | 1 | P24928 | POLR2A | More | |
Acitretin | hsa03320 | PPAR signaling pathway | 3.78E-02 | 2 | Q6PCB7, Q9UNU6 | SLC27A1, CYP8B1 | More | |
Acitretin | hsa04012 | ErbB signaling pathway | 3.31E-02 | 1 | Q13153 | PAK1 | More | |
Acitretin | hsa04024 | cAMP signaling pathway | 4.80E-02 | 1 | Q13153 | PAK1 | More | |
Acitretin | hsa04064 | NF-kappa B signaling pathway | 4.09E-03 | 8 | P10415, O00463, Q04759, Q9UDY8, Q16548, Q13315, P24522, P09341 | BCL2, TRAF5, PRKCQ, MALT1, BCL2A1, ATM, GADD45A, CXCL1 | More | |
Acitretin | hsa04070 | Phosphatidylinositol signaling system | 2.65E-02 | 2 | P29218, Q14642 | IMPA1, INPP5A | More | |
Acitretin | hsa04071 | Sphingolipid signaling pathway | 1.19E-02 | 5 | P21453, Q9H228, Q13362, Q9BX95, P10415 | S1PR1, EDG8, PPP2R5C, SGPP1, BCL2 | More | |
Acitretin | hsa04080 | Neuroactive ligand-receptor interaction | 1.71E-04 | 7 | P08311, Q15722, P21453, Q9H228, O00398, P21730, P07550 | CTSG, LTB4R, S1PR1, EDG8, P2RY10, C5AR1, ADRB2 | More | |
Acitretin | hsa04114 | Oocyte meiosis | 4.51E-03 | 5 | Q9Y6D9, P51812, Q02750, P16298, Q17RY0 | MAD1L1, RPS6KA3, MAP2K1, PPP3CB, CPEB4 | More | |
Acitretin | hsa04140 | Autophagy - animal | 3.75E-03 | 4 | P22694, Q14643, P10415, Q04759 | PRKACB, ITPR1, BCL2, PRKCQ | More | |
Acitretin | hsa04145 | Phagosome | 4.48E-02 | 5 | Q15080, P05164, O60603, P35443, P13765 | NCF4, MPO, TLR2, THBS4, HLA-DOB | More | |
Acitretin | hsa04210 | Apoptosis | 3.44E-02 | 7 | Q13315, P10415, O76075, P24522, Q16548, P43234, Q14643 | ATM, BCL2, DFFB, GADD45A, BCL2A1, CTSO, ITPR1 | More | |
Acitretin | hsa04215 | Apoptosis - multiple species | 1.56E-02 | 2 | Q13489, P10415 | BIRC3, BCL2 | More | |
Acitretin | hsa04340 | Hedgehog signaling pathway | 7.64E-04 | 3 | P22694, Q13635, P10415 | PRKACB, PTCH1, BCL2 | More | |
Acitretin | hsa04370 | VEGF signaling pathway | 2.47E-03 | 3 | P16298, Q05397, Q02750 | PPP3CB, PTK2, MAP2K1 | More | |
Acitretin | hsa04390 | Hippo signaling pathway | 2.08E-02 | 3 | P84022, Q13485, Q13489 | SMAD3, SMAD4, BIRC3 | More | |
Acitretin | hsa04392 | Hippo signaling pathway - multiple species | 1.51E-02 | 1 | Q13153 | PAK1 | More | |
Acitretin | hsa04540 | Gap junction | 2.86E-02 | 3 | P22694, P68371, Q14643 | PRKACB, TUBB2C, ITPR1 | More | |
Acitretin | hsa04612 | Antigen processing and presentation | 4.48E-02 | 5 | P13765, P26715, P26717, Q13241, P01732 | HLA-DOB, KLRC1, KLRC2, KLRD1, CD8A | More | |
Acitretin | hsa04613 | Neutrophil extracellular trap formation | 4.93E-02 | 8 | O60603, P05164, P08246, Q9UM07, Q15080, P20160, P08311, P21730 | TLR2, MPO, ELA2, PADI4, NCF4, AZU1, CTSG, C5AR1 | More | |
Acitretin | hsa04625 | C-type lectin receptor signaling pathway | 3.31E-02 | 1 | Q13153 | PAK1 | More | |
Acitretin | hsa04650 | Natural killer cell mediated cytotoxicity | 4.25E-04 | 10 | P16298, P50591, O60880, P20963, Q02750, Q13153, Q13241, P26718, P26717, P26715 | PPP3CB, TNFSF10, SH2D1A, CD247, MAP2K1, PAK1, KLRD1, KLRK1, KLRC2, KLRC1 | More | |
Acitretin | hsa04658 | Th1 and Th2 cell differentiation | 1.07E-03 | 7 | Q04759, P20963, P09693, Q14765, P23771, Q9UL17, P13765 | PRKCQ, CD247, CD3G, STAT4, GATA3, TBX21, HLA-DOB | More | |
Acitretin | hsa04659 | Th17 cell differentiation | 2.05E-03 | 9 | P25963, Q04759, P13765, Q9UL17, P23771, P84022, Q13485, P09693, P20963 | NFKBIA, PRKCQ, HLA-DOB, TBX21, GATA3, SMAD3, SMAD4, CD3G, CD247 | More | |
Acitretin | hsa04660 | T cell receptor signaling pathway | 9.38E-04 | 8 | Q9UDY8, Q04759, P10747, Q08881, Q13153, P20963, P09693, P01732 | MALT1, PRKCQ, CD28, ITK, PAK1, CD247, CD3G, CD8A | More | |
Acitretin | hsa04710 | Circadian rhythm | 1.65E-04 | 4 | O00327, O15055, Q16526, Q9Y478 | ARNTL, PER2, CRY1, PRKAB1 | More | |
Acitretin | hsa04720 | Long-term potentiation | 2.35E-02 | 3 | P16298, P51812, Q02750 | PPP3CB, RPS6KA3, MAP2K1 | More | |
Acitretin | hsa04725 | Cholinergic synapse | 3.74E-02 | 3 | P22694, Q14643, P10415 | PRKACB, ITPR1, BCL2 | More | |
Acitretin | hsa04913 | Ovarian steroidogenesis | 2.72E-02 | 2 | P42330, P22694 | AKR1C3, PRKACB | More | |
Acitretin | hsa04914 | Progesterone-mediated oocyte maturation | 7.70E-03 | 4 | Q17RY0, Q9Y6D9, P51812, Q02750 | CPEB4, MAD1L1, RPS6KA3, MAP2K1 | More | |
Acitretin | hsa04920 | Adipocytokine signaling pathway | 4.31E-02 | 2 | Q9Y478, Q96RR4 | PRKAB1, CAMKK2 | More | |
Acitretin | hsa04922 | Glucagon signaling pathway | 4.23E-02 | 4 | P22694, P06737, Q12778, Q14643 | PRKACB, PYGL, FOXO1, ITPR1 | More | |
Acitretin | hsa04924 | Renin secretion | 7.24E-05 | 3 | P22694, P07550, Q14643 | PRKACB, ADRB2, ITPR1 | More | |
Acitretin | hsa04927 | Cortisol synthesis and secretion | 2.72E-02 | 2 | Q14643, P22694 | ITPR1, PRKACB | More | |
Acitretin | hsa04928 | Parathyroid hormone synthesis, secretion and action | 1.32E-03 | 4 | Q14643, P22694, P23771, P10415 | ITPR1, PRKACB, GATA3, BCL2 | More | |
Acitretin | hsa04933 | AGE-RAGE signaling pathway in diabetic complications | 1.25E-02 | 3 | P84022, Q13485, P10415 | SMAD3, SMAD4, BCL2 | More | |
Acitretin | hsa04934 | Cushing syndrome | 4.74E-02 | 3 | Q14643, P22694, P04628 | ITPR1, PRKACB, WNT1 | More | |
Acitretin | hsa04970 | Salivary secretion | 2.11E-02 | 3 | P07550, P22694, Q14643 | ADRB2, PRKACB, ITPR1 | More | |
Acitretin | hsa04975 | Fat digestion and absorption | 3.43E-02 | 1 | O14494 | PLPP1 | More | |
Acitretin | hsa05120 | Epithelial cell signaling in Helicobacter pylori infection | 1.81E-02 | 1 | Q13153 | PAK1 | More | |
Acitretin | hsa05132 | Salmonella infection | 2.04E-02 | 4 | P25963, Q13489, P10415, Q9BQS8 | NFKBIA, BIRC3, BCL2, FYCO1 | More | |
Acitretin | hsa05135 | Yersinia infection | 2.58E-02 | 4 | Q05397, P51812, Q02750, Q96JJ3 | PTK2, RPS6KA3, MAP2K1, ELMO2 | More | |
Acitretin | hsa05145 | Toxoplasmosis | 2.78E-02 | 3 | P25963, P10415, Q13489 | NFKBIA, BCL2, BIRC3 | More | |
Acitretin | hsa05161 | Hepatitis B | 8.49E-03 | 4 | P25963, Q13485, P10415, P84022 | NFKBIA, SMAD4, BCL2, SMAD3 | More | |
Acitretin | hsa05170 | Human immunodeficiency virus 1 infection | 4.37E-02 | 4 | Q02750, P62879, P16298, Q05397 | MAP2K1, GNB2, PPP3CB, PTK2 | More | |
Acitretin | hsa05202 | Transcriptional misregulation in cancer | 2.90E-02 | 9 | Q12778, Q13315, P14780, Q16548, O15550, P05164, P08246, Q9C0K0, P24522 | FOXO1, ATM, MMP9, BCL2A1, UTX, MPO, ELA2, BCL11B, GADD45A | More | |
Acitretin | hsa05203 | Viral carcinogenesis | 4.62E-02 | 3 | Q12933, P42229, Q15283 | TRAF2, STAT5A, RASA2 | More | |
Acitretin | hsa05204 | Chemical carcinogenesis | 5.46E-03 | 2 | Q16772, P09211 | GSTA3, GSTP1 | More | |
Acitretin | hsa05210 | Colorectal cancer | 1.78E-02 | 3 | P84022, Q13485, P10415 | SMAD3, SMAD4, BCL2 | More | |
Acitretin | hsa05211 | Renal cell carcinoma | 2.42E-02 | 1 | Q13153 | PAK1 | More | |
Acitretin | hsa05212 | Pancreatic cancer | 3.52E-02 | 2 | P84022, Q13485 | SMAD3, SMAD4 | More | |
Acitretin | hsa05220 | Chronic myeloid leukemia | 1.25E-02 | 3 | Q13485, P25963, P84022 | SMAD4, NFKBIA, SMAD3 | More | |
Acitretin | hsa05222 | Small cell lung cancer | 1.50E-02 | 3 | Q13489, P10415, P25963 | BIRC3, BCL2, NFKBIA | More | |
Acitretin | hsa05226 | Gastric cancer | 2.78E-02 | 3 | P84022, Q13485, P10415 | SMAD3, SMAD4, BCL2 | More | |
Acitretin | hsa05235 | PD-L1 expression and PD-1 checkpoint pathway in cancer | 2.84E-02 | 5 | P20963, P09693, O60603, P10747, Q04759 | CD247, CD3G, TLR2, CD28, PRKCQ | More | |
Acitretin | hsa05321 | Inflammatory bowel disease | 1.17E-03 | 5 | O60603, P13765, Q14765, Q9UL17, P23771 | TLR2, HLA-DOB, STAT4, TBX21, GATA3 | More | |
Acitretin | hsa05323 | Rheumatoid arthritis | 1.60E-02 | 4 | P13765, P10747, P09341, O60603 | HLA-DOB, CD28, CXCL1, TLR2 | More | |
Acitretin | hsa05332 | Graft-versus-host disease | 3.45E-03 | 4 | P13765, P10747, P26715, Q13241 | HLA-DOB, CD28, KLRC1, KLRD1 | More | |